Valuation: 2cureX AB

Market Cap 7.43M 770K 673K 619K 577K 1.09M 73.33M 1.11M 2.89M 36.05M 2.89M 2.83M 124M P/E 2022
-4.81x
P/E 2023 -1.09x
Enterprise Value -5.97M -619K -542K -498K -464K -880K -58.98M -893K -2.32M -28.99M -2.33M -2.28M -99.91M EV / Sales 2022
29.3x
EV / Sales 2023 7.46x
Free-Float
61.98%
Yield 2022 *
-
Yield 2023 -
1 day-5.66%
1 week+8.23%
1 month+14.16%
3 months+81.82%
6 months+271.75%
Current year+289.11%
1 week 1.86
Extreme 1.86
2.3
1 month 1.64
Extreme 1.64
2.4
Current year 0.52
Extreme 0.52
3.27
1 year 0.51
Extreme 0.514
4.2
3 years 0.2
Extreme 0.203
5.52
5 years 0.2
Extreme 0.203
19.4
10 years 0.2
Extreme 0.203
31.5
Manager TitleAgeSince
Chief Operating Officer 67 31/12/2005
Chief Executive Officer 73 -
Chief Executive Officer 50 28/12/2023
Director TitleAgeSince
Chairman 73 15/12/2024
Director/Board Member 67 31/12/2005
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-5.66%+8.23%-46.95%-50.00% 6.62M
-4.63%-5.64%+107.49%+129.05% 4.55B
-5.27%+1.10%+79.58%+217.22% 3.39B
+2.15%+5.68%-25.44%-39.45% 2.07B
+8.56%+1.41%+146.29%-39.30% 1.92B
-0.21%+1.28%+51.72%+243.82% 1.51B
-1.79%-2.89%+126.22%-51.45% 891M
+1.38%+4.82%-8.85%+41.45% 874M
+2.32%+6.54%-34.61%-16.56% 498M
-0.83%+8.52%+3.06% - 473M
Average -0.40%+1.22%+39.85%+48.31% 1.62B
Weighted average by Cap. -1.11%+0.93%+71.33%+96.48%

Financials

2022 2023
Net sales 3.37M 349K 305K 281K 262K 496K 33.26M 504K 1.31M 16.35M 1.31M 1.28M 56.34M 2.95M 306K 267K 245K 229K 434K 29.09M 441K 1.15M 14.3M 1.15M 1.12M 49.28M
Net income -29.77M -3.09M -2.7M -2.48M -2.31M -4.38M -294M -4.45M -11.57M -144M -11.59M -11.34M -498M -32.52M -3.37M -2.95M -2.71M -2.52M -4.79M -321M -4.86M -12.64M -158M -12.66M -12.38M -544M
Net Debt -44.89M -4.65M -4.07M -3.74M -3.49M -6.61M -443M -6.71M -17.45M -218M -17.47M -17.1M -751M -13.4M -1.39M -1.21M -1.12M -1.04M -1.97M -132M -2M -5.21M -65.04M -5.22M -5.1M -224M
Logo 2cureX AB
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
Employees
14
Date Price Change Volume
03/07/26 SEK 2.000 -5.66% 57,577
02/07/26 SEK 2.120 -5.78% 27,865
01/07/26 SEK 2.250 +12.50% 38,085
30/06/26 SEK 2.000 +4.93% 38,577
29/06/26 SEK 1.906 +3.14% 125,333
  1. Stock Market
  2. Stocks
  3. 2CUREX Stock